Axsome Therapeutics Stock Performance
| AXSM Stock | USD 180.84 4.70 2.53% |
On a scale of 0 to 100, Axsome Therapeutics holds a performance score of 11. The firm shows a Beta (market volatility) of -0.0973, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Axsome Therapeutics are expected to decrease at a much lower rate. During the bear market, Axsome Therapeutics is likely to outperform the market. Please check Axsome Therapeutics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Axsome Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Axsome Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.95 | Five Day Return (1.62) | Year To Date Return 2.16 | Ten Year Return 3.3 K | All Time Return 2 K |
1 | PNC Financial Services Group Inc. Reduces Stock Holdings in Axsome Therapeutics, Inc. AXSM | 11/28/2025 |
2 | Voya Investment Management LLC Decreases Stake in Axsome Therapeutics, Inc. AXSM - MarketBeat | 12/23/2025 |
3 | Disposition of 29450 shares by Tabuteau Herriot of Axsome Therapeutics at 172.33 subject to Rule 16b-3 | 01/06/2026 |
4 | Assessing Axsome Therapeutics Valuation After Recent Share Price Momentum | 01/14/2026 |
5 | Assessing Axsome Therapeutics After An 86 percent One-Year Share Price Surge | 01/16/2026 |
6 | Disposition of 7500 shares by Ari Maizel of Axsome Therapeutics at 184.44 subject to Rule 16b-3 | 01/21/2026 |
7 | Disposition of 12000 shares by Pizzie Nick of Axsome Therapeutics at 187.92 subject to Rule 16b-3 | 01/22/2026 |
8 | Piper Sandler Bullish on Axsome Therapeutics Ahead of Likely Auvelity Label Expansion by April 30 | 01/23/2026 |
9 | J. Safra Sarasin Holding AG Has 1.08 Million Stake in Axsome Therapeutics, Inc. AXSM - MarketBeat | 01/29/2026 |
10 | 1 High-Flying Stock With More Upside Ahead | 02/03/2026 |
11 | Axsome Therapeutics Valuation After FDA Review Focus And Strong CNS Growth Momentum | 02/04/2026 |
| Begin Period Cash Flow | 386.2 M | |
| Total Cashflows From Investing Activities | -270 K |
Axsome Therapeutics Relative Risk vs. Return Landscape
If you would invest 13,780 in Axsome Therapeutics on November 9, 2025 and sell it today you would earn a total of 4,304 from holding Axsome Therapeutics or generate 31.23% return on investment over 90 days. Axsome Therapeutics is currently generating 0.5011% in daily expected returns and assumes 3.4898% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Axsome, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Axsome Therapeutics Target Price Odds to finish over Current Price
The tendency of Axsome Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 180.84 | 90 days | 180.84 | about 10.92 |
Based on a normal probability distribution, the odds of Axsome Therapeutics to move above the current price in 90 days from now is about 10.92 (This Axsome Therapeutics probability density function shows the probability of Axsome Stock to fall within a particular range of prices over 90 days) .
Axsome Therapeutics Price Density |
| Price |
Predictive Modules for Axsome Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Axsome Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Axsome Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Axsome Therapeutics is not an exception. The market had few large corrections towards the Axsome Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Axsome Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Axsome Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.49 | |
β | Beta against Dow Jones | -0.1 | |
σ | Overall volatility | 17.84 | |
Ir | Information ratio | 0.12 |
Axsome Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Axsome Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Axsome Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Axsome Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 515.6 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Axsome Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Axsome Therapeutics Valuation After FDA Review Focus And Strong CNS Growth Momentum |
Axsome Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Axsome Stock often depends not only on the future outlook of the current and potential Axsome Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Axsome Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 47.9 M | |
| Cash And Short Term Investments | 315.4 M |
Axsome Therapeutics Fundamentals Growth
Axsome Stock prices reflect investors' perceptions of the future prospects and financial health of Axsome Therapeutics, and Axsome Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Axsome Stock performance.
| Return On Equity | -2.75 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 9.25 B | ||||
| Shares Outstanding | 50.41 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 126.87 X | ||||
| Price To Sales | 16.24 X | ||||
| Revenue | 385.69 M | ||||
| Gross Profit | 515.6 M | ||||
| EBITDA | (272.6 M) | ||||
| Net Income | (287.22 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 192.96 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 1.47 X | ||||
| Cash Flow From Operations | (128.41 M) | ||||
| Earnings Per Share | (4.67) X | ||||
| Market Capitalization | 9.12 B | ||||
| Total Asset | 568.5 M | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 254.96 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
About Axsome Therapeutics Performance
By examining Axsome Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Axsome Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Axsome Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 198.29 | 252.16 | |
| Return On Tangible Assets | (0.51) | (0.53) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.45) | (0.48) | |
| Return On Equity | (5.79) | (6.08) |
Things to note about Axsome Therapeutics performance evaluation
Checking the ongoing alerts about Axsome Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Axsome Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Axsome Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 515.6 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Axsome Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Axsome Therapeutics Valuation After FDA Review Focus And Strong CNS Growth Momentum |
- Analyzing Axsome Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Axsome Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Axsome Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Axsome Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Axsome Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Axsome Therapeutics' stock. These opinions can provide insight into Axsome Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.67) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.